VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SBFM
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
SBFMSunshine Biopharma, Inc.
$2.11$1M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

SBFM logoSunshine Biopharma, Inc.(SBFM)Earnings, Financials & Key Ratios

SBFM•NASDAQ
$2.14
Price updated Jul 2, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryTherapy-focused branded biopharma
AboutSunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.Show more
  • Revenue$36M+4.1%
  • EBITDA-$4M+25.8%
  • Net Income-$6M-16.4%
  • EPS (Diluted)-14.40+80.3%
  • Gross Margin32.84%+7.3%
  • EBITDA Margin-11.42%+28.7%
  • Operating Margin-12.34%+26.0%
  • Net Margin-16.46%-11.8%
  • ROE-25.68%-11.8%

SBFM Price & Volume

Sunshine Biopharma, Inc. (SBFM) stock price & volume — 10-year historical chart

Loading chart...

Stagnant Revenue Growth Masks Persistent Liquidity Erosion

Investment Thesis • Updated 2026Q1

VerdictNegative: The company's cash position has declined from $17.4M in 2024Q1 to $6.9M in 2026Q1
Growth:Decelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical milestone funding gap

Key Thesis Takeaways

  • Sunshine Biopharma faces a challenging outlook as its core nutritional supplement business experiences a revenue contraction of 9.1% in 2026Q1, signaling potential market saturation.
  • The company's hybrid model remains fundamentally strained, with persistent operating losses and a deepening retained earnings deficit of $76.3M as of 2026Q1.
  • Investors should remain cautious as the firm's reliance on cash reserves to fund R&D, coupled with a declining cash position of $6.9M, suggests significant future capital requirements.

Verdict Logic

indicating a rapid depletion of liquidity that necessitates further capital raises.

SBFM Growth Metrics

Sunshine Biopharma, Inc. (SBFM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years170.86%
5 Years247.73%
3 Years102.91%
TTM-2.04%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-20.06%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM28.45%

Return on Capital

10 Years-303.38%
5 Years-73.48%
3 Years-21.84%
Last Year-18.71%

Latest SBFM News

Recent stock market news and headlines for Sunshine Biopharma, Inc. (SBFM)

Accesswire·Jun 25, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)

FORT LAUDERDALE, FL / ACCESS Newswire / June 25, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the brand name breast cancer drug, Arimidex®.

Peers Comparison

Key metrics vs top competitors for Sunshine Biopharma, Inc. (SBFM)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SBFM logoSBFMSunshine Biopharma, Inc.Current
$2.14$1.07M-0.154.11%-16.46%-25.68%—
CRVS logoCRVSCorvus Pharmaceuticals, Inc.
$14.76$1.24B-27.85——-38.92%—
IMVT logoIMVTImmunovant, Inc.
$38.14$7.83B-13.77——-68.16%—
NUVB logoNUVBNuvation Bio Inc.
$5.42$1.88B-9.03698.96%-102.06%-44.1%—
TPVG logoTPVGTriplePoint Venture Growth BDC Corp.
$5.07$205.84M4.1636.55%-19.55%-3.39%—
SNDX logoSNDXSyndax Pharmaceuticals, Inc.
$20.89$1.84B-6.35627.84%-112.01%-256.66%—

Compare SBFM vs Peers

Sunshine Biopharma, Inc. (SBFM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CRVS

Most directly comparable listed peer for SBFM.

Scale Benchmark

vs MEDP

Larger-name benchmark to compare SBFM against a more recognizable public peer.

Peer Set

Compare Top 5

vs CRVS, IMVT, NUVB, TPVG

SBFM SEC Filings & Documents

Sunshine Biopharma, Inc. (SBFM) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 19, 2026·SEC

Material company update

Apr 9, 2026·SEC

Material company update

Mar 9, 2026·SEC

10-K Annual Reports

3
FY 2026

Apr 3, 2026·SEC

FY 2025

Apr 1, 2025·SEC

FY 2024

Mar 28, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 13, 2026·SEC

FY 2025

Nov 13, 2025·SEC

FY 2025

Aug 12, 2025·SEC

Get notified when SBFM posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SBFM Frequently Asked Questions

Sunshine Biopharma, Inc. (SBFM) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Sunshine Biopharma, Inc.'s revenue?

Sunshine Biopharma, Inc. (SBFM) reported $35.5M in revenue for fiscal year 2025.

How fast is Sunshine Biopharma, Inc. growing?

Sunshine Biopharma, Inc. (SBFM) grew revenue by 4.1% over the past year. Growth has been modest.

Is SBFM profitable?

Sunshine Biopharma, Inc. (SBFM) reported a net loss of $6.0M for fiscal year 2025.

Dividend & Returns
What is SBFM's return on equity?

Sunshine Biopharma, Inc. (SBFM) has a return on equity (ROE) of -25.7%. Negative ROE indicates the company is unprofitable.

What is Sunshine Biopharma, Inc.'s free cash flow?

Sunshine Biopharma, Inc. (SBFM) had negative free cash flow of $5.5M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in SBFM back in 2007?

Total return calculator · dividends reinvested · 19+ years of data

See returns →